New studies emphasize how peptide-based launches, the core of the Gate2Brain technological platform, a member of CATALONIA.HEALTH, are poised to revolutionise drug administration through the blood-brain barrier. Gate2Brain’s technology, a spinoff of the University of Barcelona (UB), the Institut de Recerca Sant Joan de Déu (IRSJD) – Hospital Sant Joan de Déu (SJD), also members of CATALONIA.HEALTH, and the Institute for Research in Biomedicine (IRB Barcelona) is especially relevant for antibody-based therapies that, despite their potential, are often limited by their low accessibility to the brain.
The two articles published in Molecular Pharmaceutics, in which Meritxell Teixidó, CEO and CSO of Gate2Brain took part in them, have put the focus and robustly validated the versatility of the company's technological platform as a system capable of transporting a wide range of therapeutic agents through the blood-brain barrier (BHE). These findings demonstrate that, whether delivering monoclonal antibodies or other drug modalities, the innovative brain shuttle peptides, a key piece of the Gate2Brain platform, can overcome one of the greatest challenges of modern medicine.
These studies reinforce the concept that advanced peptide-based brain shuttle technologies, the central piece of the Gate2Brain’s platform, are dynamic and adaptable tools to overcome the challenges of drug administration in the brain. This advance is a great step towards accelerating the clinical translation of new treatments for a wide variety of neurological disorders, especially those in which a therapeutic candidate needs a more efficient transport system, thus offering real hope to those suffering from brain diseases and their families.
Related news:
Comments